# Oncology Institute share price (The Oncology Institute, Inc., TOI)

> The Oncology Institute, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. TOI · Healthcare · Medical Care Facilities · data as of 3 August 2026. Page: https://www.sectoralpha.in/us/stocks/toi

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $5.13 (+37.5% in a year)
- Revenue (Mar 2026): $147 M (+41.2% on a year ago)
- Profit (Mar 2026): −$2.5 M
- Operating margin: −4.4% (+5.1 points on a year ago)
- ROE: 386%, FY25
- ROIC: −30.3%, against a 6.4% cost of capital: −36.7 points

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Oncology Institute share price? The Oncology Institute, Inc.'s share price was $5.13 at the close on 3 August 2026. That is 32.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $6, and at that close it sat 78% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 15 weeks in a row. Over the last 1 year the share price moved +64% while the S&P 500 moved +20%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Oncology Institute pay? The Oncology Institute, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Oncology Institute on? Oncology Institute is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Oncology Institute profitable? The Oncology Institute, Inc. posted a net loss of $2.5 M in the Mar 2026 quarter. The full FY25 year was a loss of $60.6 M. That loss is 1.7% of the quarter's revenue. The same quarter a year earlier lost $19.6 M. 12 of the last 12 reported quarters were loss-making. ## How much revenue does Oncology Institute make, and is it growing? The Oncology Institute, Inc. reported $147 M of revenue in the Mar 2026 quarter, +41.2% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 25.4% a year on average. The last full year, FY25, came in at $503 M. The last four reported quarters add to $546 M. FY25 revenue was $503 M, +27.8% on the year before. Recent pace: the last four quarters grew +35.3% on average, against 25.4% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +35.4%, against +26.2% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Oncology Institute keep? The Oncology Institute, Inc.'s operating margin was −4.4% in the Mar 2026 quarter, 5.1 percentage points higher than the same quarter a year ago. Across 5 years it has been between −32.5% and −7.2%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +5.1 percentage points on the year while gross margin changed −0.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Oncology Institute's profit turning into cash? The Oncology Institute, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used $24.6 M of cash, against −$60.6 M of profit. After $3.2 M of spending on assets, free cash was −$27.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Oncology Institute's cash go? The Oncology Institute, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $11.6 M on assets over the last 3 years. Averaged over those years that is 0.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $11.6 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Oncology Institute's P/E ratio, and how does it compare with its own history? The Oncology Institute, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values The Oncology Institute, Inc. at 1.3× its FY25 revenue of $503 M. The P/E comes back here once profit turns positive. ## Is the Oncology Institute business getting better or worse? The Oncology Institute, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Oncology Institute earn on its capital? The Oncology Institute, Inc. earned a ROE of 386% in FY25. That is up from a low of −1,802% in FY24. Its return on capital used (ROIC) is 36.7 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −12.1% net margin and 3.05× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −12.1% net margin × 3.05× asset turnover × −10.47× leverage (assets divided by equity) ≈ 386.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −30.3% − 6.4% = −36.7 percentage points. The 6.4% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −30.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −42.4%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Oncology Institute have too much debt? The Oncology Institute, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 0.00 in FY21 to −6.60 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Oncology Institute shareholding pattern? 7.3% of The Oncology Institute, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 4.8 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Oncology Institute from balance-sheet trouble? For The Oncology Institute, Inc., the Z-score is 1.84. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.84 is in the grey area, neither clearly safe nor clearly in trouble. ## How does Oncology Institute rank in its industry? There is no score against its industry: The Oncology Institute, Inc. is not among the largest members shown in this industry comparison for Medical Care Facilities. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Oncology Institute compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Oncology Institute in size? Oncology Institute is the 33rd largest of 38 Medical Care Facilities companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Nutex Health Inc., InnovAge Holding Corp. and GMR Solutions Inc. Just below it: Charming Medical, Cross Country Healthcare, Inc. and Strata Critical Medical, Inc. ### Medical Care Facilities companies close in size

1. [Nutex Health Inc.](https://www.sectoralpha.in/us/stocks/nutx) $1.2 billion
2. [InnovAge Holding Corp.](https://www.sectoralpha.in/us/stocks/innv) $1.2 billion
3. [GMR Solutions Inc.](https://www.sectoralpha.in/us/stocks/gmrs) $885 million
4. The Oncology Institute, Inc. $646 million
5. [Charming Medical Limited](https://www.sectoralpha.in/us/stocks/mcta) $504 million
6. [Cross Country Healthcare, Inc.](https://www.sectoralpha.in/us/stocks/ccrn) $428 million
7. [Strata Critical Medical, Inc.](https://www.sectoralpha.in/us/stocks/srta) $393 million

[All 38 Medical Care Facilities companies, largest first](https://www.sectoralpha.in/us/sectors/medical-care-facilities#all-companies)

### Companies close in size in other industries

1. [Hello Group Inc.](https://www.sectoralpha.in/us/stocks/momo) $638 million · Internet Content & Information
2. [Velocity Financial, Inc.](https://www.sectoralpha.in/us/stocks/vel) $637 million · Mortgage Finance
3. The Oncology Institute, Inc. $637 million
4. [AH REALTY TRUST INC](https://www.sectoralpha.in/us/stocks/ahrt) $636 million · REIT - Diversified
5. [Enovix Corporation](https://www.sectoralpha.in/us/stocks/envx) $636 million · Electrical Equipment & Parts

## What else do people ask about Oncology Institute? ### What were Oncology Institute's latest quarterly results? The Oncology Institute, Inc. reported revenue of $147 M and a net loss of $2.5 M for the Mar 2026 quarter. Earnings per share were −$0.02. The operating margin was −4.4%, 5.1 percentage points higher than a year earlier (as of 3 August 2026). ### What is Oncology Institute's market cap? The Oncology Institute, Inc.'s market capitalisation is $646 M at a stock price of $5.13. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 August 2026). ### How is Oncology Institute performing? The Oncology Institute, Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 15 weeks running. This describes what the data did, not a rating (as of 3 August 2026). ### Will Oncology Institute's stock price go up? This page does not forecast The Oncology Institute, Inc.'s stock price. What it shows instead: the stock price is $5.13. Nobody can reliably say which way a price will move, and this site does not try (as of 3 August 2026). ### Where is Oncology Institute in its business cycle? The Oncology Institute, Inc.'s FY25 operating margin was −7.2%, against a 5-year range of −32.5% to −7.2%: the middle of its own range, neither a peak nor a low. The latest quarter was −4.4%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 August 2026). ### What could break the Oncology Institute story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 August 2026). ### Is Oncology Institute a stock worth studying right now? What the numbers show: The Oncology Institute, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 August 2026). This is research, not advice. We’re not SEBI-registered.